Last reviewed · How we verify
Etanercept / Autoinjector A
Etanercept / Autoinjector A is a TNF inhibitor (TNF receptor fusion protein) Small molecule drug developed by Amgen. It is currently in Phase 3 development for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis. Also known as: Enbrel®.
Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
Amgen is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Etanercept / Autoinjector A |
|---|---|
| Also known as | Enbrel® |
| Sponsor | Amgen |
| Drug class | TNF inhibitor (TNF receptor fusion protein) |
| Target | TNF-alpha and TNF-beta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Etanercept works by acting as a soluble TNF receptor that captures circulating TNF-alpha and TNF-beta, preventing them from binding to cell-surface TNF receptors and triggering inflammatory cascades. This reduces systemic inflammation and immune activation in TNF-driven diseases. The autoinjector formulation provides a convenient subcutaneous delivery mechanism for patient self-administration.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Juvenile idiopathic arthritis
- Plaque psoriasis
- Polyarticular course juvenile rheumatoid arthritis
Common side effects
- Injection site reactions (erythema, itching, pain)
- Upper respiratory tract infections
- Headache
- Dizziness
- Serious infections (including tuberculosis)
- Autoimmune phenomena (anti-dsDNA antibodies)
Key clinical trials
- A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis
- Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (PHASE4)
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (PHASE3)
- Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis (PHASE3)
- Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (PHASE4)
- Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept (PHASE3)
- Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis (PHASE3)
- Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etanercept / Autoinjector A CI brief — competitive landscape report
- Etanercept / Autoinjector A updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Etanercept / Autoinjector A
What is Etanercept / Autoinjector A?
How does Etanercept / Autoinjector A work?
What is Etanercept / Autoinjector A used for?
Who makes Etanercept / Autoinjector A?
Is Etanercept / Autoinjector A also known as anything else?
What drug class is Etanercept / Autoinjector A in?
What development phase is Etanercept / Autoinjector A in?
What are the side effects of Etanercept / Autoinjector A?
What does Etanercept / Autoinjector A target?
Related
- Drug class: All TNF inhibitor (TNF receptor fusion protein) drugs
- Target: All drugs targeting TNF-alpha and TNF-beta
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Psoriatic arthritis
- Also known as: Enbrel®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing